Arcus Biosciences

1. PEAK-1 / PEAK-20 enrollment doneYear-end 2026PEAK-1 / PEAK-20 enrollment done, Year-end 2026, notable
2. I&I portfolio MRGPRX2 antagonist trialLate 2026 / Early 2027I&I portfolio MRGPRX2 antagonist trial, Late 2026 / Early 2027, routine
3. ARC-20 cohorts cas+axitinib trial start4Q 2026ARC-20 cohorts cas+axitinib trial start, 4Q 2026, notable
4. Casdatifan Ph3 interimOct 20, 2026Casdatifan Ph3 interim, Oct 20, 2026, major
5. Quemliclustat Ph3 topline1H 2027Quemliclustat Ph3 topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.